← Back to Search

Monoclonal Antibodies

Bevacizumab + Interleukin-2 for Kidney Cancer

Phase 2
Waitlist Available
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed metastatic renal cell carcinoma (RCC) with predominantly clear cell histology
Karnofsky performance status ≥ 80%
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying bevacizumab and interleukin-2 in treating patients with metastatic kidney cancer.

Who is the study for?
This trial is for adults with metastatic kidney cancer, specifically clear cell renal carcinoma. They must be in good physical condition (Karnofsky score ≥ 80%), have normal organ function, and no serious heart issues or other cancers within the last 5 years. Pregnant women can't join, and participants must use contraception.Check my eligibility
What is being tested?
The study tests combining bevacizumab, a monoclonal antibody that blocks tumor blood supply, with interleukin-2 which may activate white blood cells to kill cancer cells. The goal is to see if this combination works better for treating metastatic kidney cancer.See study design
What are the potential side effects?
Bevacizumab might cause high blood pressure, bleeding problems, slow wound healing or increase the risk of developing holes in your gastrointestinal tract. Interleukin-2 can lead to flu-like symptoms such as fever and chills, fatigue, nausea or vomiting.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney cancer is confirmed and mainly consists of clear cells.
Select...
I am mostly self-sufficient and active.
Select...
I do not have inflammatory bowel disease or any serious autoimmune condition.
Select...
My kidney function is normal, based on creatinine levels or clearance.
Select...
I have never had a stroke or a mini-stroke.
Select...
I don't have any major health issues like uncontrolled diabetes or infections.
Select...
I do not have any serious, nonhealing wounds or broken bones.
Select...
I am not currently experiencing any bleeding.
Select...
I don't have a history of serious bleeding or blood clotting disorders.
Select...
I have never had deep vein clots, significant blood vessel issues, or other clotting events.
Select...
My blood pressure is under 150/100 mm Hg.
Select...
My cancer can be measured by tests.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free and overall survival
Response
Secondary outcome measures
Comparison of response and survival with historical data
Correlation of serum VEGF levels, DC function, TCR zeta chain expression, and arginase or arginine levels with toxicity, response, and survival
Pharmacokinetics and pharmacodynamics
+3 more

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
358 Previous Clinical Trials
26,011 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,581 Total Patients Enrolled
Fairooz F. Kabbinavar, MDStudy ChairJonsson Comprehensive Cancer Center
4 Previous Clinical Trials
602 Total Patients Enrolled

Media Library

Bevacizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT00301990 — Phase 2
Kidney Cancer Research Study Groups:
Kidney Cancer Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT00301990 — Phase 2
Bevacizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00301990 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any documented side effects of this treatment?

"While there is some evidence that this intervention may be safe, as it is only a Phase 2 trial, there is currently no data supporting its efficacy. Therefore, our team has given it a score of 2."

Answered by AI

Are there any available vacancies for volunteers in this clinical trial?

"No, this particular study is not looking for new patients at the moment. However, it's worth noting that there are 432 other trials currently recruiting. The original posting date was September 1st, 2005 and the most recent update was on January 9th, 2014 according to clinicaltrials.gov"

Answered by AI

Could you please list the hospitals where this trial is taking place?

"Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center in Lebanon, UPMC Cancer Centers in Pittsburgh, and University of Virginia Cancer Center in Charlottesville are all participating in this trial. Including these locations, 11 medical centres are taking part."

Answered by AI
~3 spots leftby Mar 2025